Alemtuzumab Improves Brain MRI Outcomes in Patients With Active Relapsing-Remitting Multiple Sclerosis: 3-Year Follow-up of the CARE-MS Studies

被引：0
|
作者：
Arnold, Douglas
Cohen, Jeffrey
Barkhof, Frederik
Selmaj, Krzysztof
Margolin, David
Palmer, Jeffrey
Fox, Edward
机构：
来源：
NEUROLOGY | 2014年 / 83卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E35 / E36
页数：2
相关论文
共 50 条
  • [31] Durable Reduction in MRI Disease Activity With Alemtuzumab in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Were Treatment-Naive: 6-Year Follow-up of the CARE-MS I Study
    Arnold, Douglas L.
    Barnett, Michael
    Comi, Giancarlo
    Giovannoni, Gavin
    Pelletier, Daniel
    Rovira, Alex
    Schippling, Sven
    Van Wijmeersch, Bart
    Margolin, David H.
    Thangavelu, Karthinathan
    Traboulsee, Anthony
    NEUROLOGY, 2017, 88
  • [32] Efficacy and safety of alemtuzumab in 150 patients with active relapsing-remitting MS: two-year follow-up in France
    Ayrignac, X.
    Collongues, N.
    De Seze, J.
    Vermersch, P.
    Brassat, D.
    Biotti, D.
    Carra-Dalliere, C.
    Charif, M.
    Vukusic, S.
    Durand-Dubief, F.
    Edan, G.
    Lepage, E.
    Deburghgraeve, V.
    Maillart, E.
    Papeix, C.
    Alla, P.
    Berger, E.
    Bourre, B.
    Casez, O.
    Pittion, S.
    Debouverie, M.
    Derache, N.
    Defer, G.
    Gout, O.
    Deschamps, R.
    Tourbah, A.
    Zagnoli, F.
    Ruet, A.
    Ouallet, J. C.
    Brochet, B.
    Manchon, E.
    Moreau, T.
    Fromont, A.
    Clavelou, P.
    Guennoc, A-M.
    Camdessanche, J. P.
    Carpentier, A.
    Coman, I.
    Audoin, B.
    Pelletier, J.
    Magy, L.
    Wiertlewski, S.
    Laplaud, D.
    Ciron, J.
    De Broucker, T.
    Frenay, C. Lebrun
    Cohen, M.
    Labauge, P.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 604 - 605
  • [33] Alemtuzumab efficacy and safety were maintained over 8 years in relapsing-remitting multiple sclerosis patients with highly active disease from CARE-MS I: TOPAZ study follow-up
    Limmroth, V.
    Achiron, A.
    Bass, A. D.
    Bertolotto, A.
    Brandes, D.
    Chinea, A.
    Garcia, J. R.
    Naismith, R. T.
    Schippling, S.
    Sharrack, B.
    Sousa, L.
    Tintore, M.
    Traboulsee, A.
    Uitdehaag, B. M. J.
    Ziemssen, T.
    Choudhry, Z.
    Daizadeh, N.
    Pelletier, D.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 535 - 536
  • [34] Alemtuzumab improves clinical outcomes over 4 years in patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a: CARE-MS II extension study 4-year follow-up
    Boyko, A. N.
    Barnett, M.
    Brassat, D.
    Dive, D.
    Hupperts, R. M. M.
    Lycke, J.
    Montalban, X.
    Sharrack, B.
    Wray, S.
    Margolin, D. H.
    Thangavelu, K.
    Chirieac, M.
    Wiendl, H.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 326 - 327
  • [35] Alemtuzumab Improves Patient-reported Quality of Life Outcomes in Patients With Relapsing-remitting Multiple Sclerosis: Results From the CARE-MS I Extension Study
    Arroyo, Rafael
    Guo, Jennifer D.
    Zhang, Wei
    Thangavelu, Karthinathan
    Chung, Luke
    Moon, Jungyoon
    Keith, Michael
    Cella, David
    NEUROLOGY, 2018, 90
  • [36] Lymphocyte counts and infection risk among relapsing-remitting multiple sclerosis patients treated with alemtuzumab (CARE-MS II)
    Havrdova, E.
    Arnold, D. L.
    Cohen, J. A.
    Coles, A. J.
    Confavreux, C.
    Fox, E. J.
    Hartung, H. -P.
    Selmaj, K. W.
    Weiner, H. L.
    Miller, T.
    Twyman, C. L.
    Lake, S. L.
    Margolin, D. H.
    Panzara, M. A.
    Compston, D. A. S.
    JOURNAL OF NEUROLOGY, 2013, 260 : S120 - S120
  • [37] Alemtuzumab improves patient-reported quality of life in relapsing-remitting multiple sclerosis: CARE-MS I and II phase 3 trials
    Selmaj, K.
    Arnold, D. L.
    Cohen, J.
    Coles, A. J.
    Confavreux, C.
    Fox, E. J.
    Hartung, H. P.
    Havrdova, E.
    Weiner, H.
    Brinar, V.
    Boscoe, A.
    Lake, S. L.
    Margolin, D. H.
    Panzara, M.
    Rizzo, M.
    Compston, A.
    JOURNAL OF NEUROLOGY, 2012, 259 : S65 - S66
  • [38] Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
    Giovannoni, Gavin
    Cohen, Jeffrey A.
    Coles, Alasdair J.
    Hartung, Hans-Peter
    Havrdova, Eva
    Selmaj, Krzysztof W.
    Margolin, David H.
    Lake, Stephen L.
    Kaup, Susan M.
    Panzara, Michael A.
    Compston, D. Alastair S.
    NEUROLOGY, 2016, 87 (19) : 1985 - 1992
  • [39] Durable Improvement in Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a and Initiated Alemtuzumab: CARE-MS I Extension Study 4-Year Follow-up
    Oreja-Guevara, Celia
    Alroughani, Raed
    Brassat, David
    Boyko, Alexey N.
    McCombe, Pamela
    Steingo, Brian
    Van Wijmeersch, Bart
    Margolin, David H.
    Thangavelu, Karthinathan
    Rodriguez, Claudio E.
    Vermersch, Patrick
    NEUROLOGY, 2017, 88
  • [40] Alemtuzumab Reduces Serum Neurofilament Light Chain Levels in Relapsing-Remitting Multiple Sclerosis Patients with Highly Active Disease: CARE-MS I
    Kuhle, Jens
    Daizadeh, Nadia
    Barro, Christian
    Michalak, Zuzanna
    Leppert, David
    Godin, Jean
    Shankara, Srinivas
    Samad, Tarek
    Jacobs, Alan
    Chung, Luke
    Roesch, Nora
    Kaiser, Carina
    Havari, Evis
    Kappos, Ludwig
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 20 - 21
12345